{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.52","value":"60.5"}]}],"title":"Participant Disease Activity - Baseline (n=2039)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.03","value":"34.4"}]}],"title":"Participant Disease Activity - Week 24 (n=1989)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.25","value":"31.7"}]}],"title":"Participant Disease Activity - Week 48 (n=1840)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.75","value":"29.2"}]}],"title":"Participant Disease Activity - Week 108 (n=1621)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.16","value":"28.5"}]}],"title":"Participant Disease Activity - Week 156 (n=1515)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.72","value":"27.4"}]}],"title":"Participant Disease Activity - Week 204 (n=1427)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.50","value":"27.4"}]}],"title":"Participant Disease Activity - Week 264 (n=1328)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.04","value":"57.3"}]}],"title":"Physician Disease Activity - Baseline (n=2043)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.22","value":"26.8"}]}],"title":"Physician Disease Activity - Week 24 (n=1990)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.93","value":"22.3"}]}],"title":"Physician Disease Activity - Week 48 (n=1830)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.59","value":"18.6"}]}],"title":"Physician Disease Activity - Week 108 (n=1619)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.21","value":"17.4"}]}],"title":"Physician Disease Activity - Week 156 (n=1516)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.49","value":"15.6"}]}],"title":"Physician Disease Activity - Week 204 (n=1413)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.51","value":"15.1"}]}],"title":"Physician Disease Activity - Week 264 (n=1330)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.00","value":"54.9"}]}],"title":"Participant Pain - Baseline (n=2041)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.56","value":"31.0"}]}],"title":"Participant Pain - Week 24 (n=1991)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.76","value":"28.0"}]}],"title":"Participant Pain - Week 48 (n=1842)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.52","value":"26.6"}]}],"title":"Participant Pain - Week 108 (n=1622)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.90","value":"26.2"}]}],"title":"Participant Pain - Week 156 (n=1517)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.05","value":"25.3"}]}],"title":"Participant Pain - Week 204 (n=1428)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.72","value":"25.1"}]}],"title":"Participant Pain - Week 264 (n=1329)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2067"}],"units":"Participants"}],"description":"Participant's made a global assessment of their current disease activity on a 100 mm horizontal visual analogue scale (VAS). The left end of the scale indicated \"no disease activity\" (symptom-free and no arthritis symptoms, score = 0) and the right end indicated \"maximum disease activity\" (maximum arthritis disease activity, score = 100). The participant's treating physician made a global assessment of the participant's current disease activity on a 100 mm horizontal VAS. The left end of the scale indicated \"no disease activity\" (symptom-free and no arthritis symptoms, score = 0) and the right end indicated \"maximum disease activity\" (maximum arthritis disease activity, score = 100). Participant's made an assessment of their current level of pain on a 100 mm horizontal VAS. The left end of the scale indicated \"no pain\" (score = 0) and the right end of the scale indicated \"unbearable pain\" (score = 100).","dispersionType":"Standard Deviation","groups":[{"description":"Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.","id":"OG000","title":"Tocilizumab"}],"paramType":"MEAN","populationDescription":"All-exposure population: All participants who entered this study and received at least 1 dose of tocilizumab in either this extension study or in a core study. Only participants with available data were included in the analysis.","timeFrame":"Baseline to Week 264","title":"Disease Activity and Pain at Baseline and Weeks 24, 48, 108, 156, 204, and 264","type":"SECONDARY","unitOfMeasure":"mm"}